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Medicine and the community
rheumatogenic Group A streptococci subse-
quently develop RF.4,5
Various potential markers of susceptibility
to RF have been investigated, including
blood groups and human leukocyte antigen
(HLA) subtypes, but findings have often
been inconsistent.6-8 A non-HLA B-cell anti-
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Objective:  To test the B-cell antigen D8/17 as a marker of past rheumatic fever (RF) 
in a predominantly Aboriginal Australian population, and to evaluate technical 
modifications to allow its use in remote settings.
Design and setting:  Cross-sectional survey in a remote Aboriginal community, 
a regional tertiary referral hospital and a tertiary paediatric centre in Melbourne.
cipants:  106 people, including three with acute RF, 38 with a history of past RF, 
latives of these people, and 45 healthy controls.
 outcome measure:  D8/17 expression in B cells.
lts:  Blood was collected from each participant and the expression of D8/17 
D19 in each sample was analysed by flow cytometry. The mean proportion of 
7-positive B cells was 39.3% (SD, 11.8) in patients with previous RF, 22.5% (SD, 5.2) 
t-degree relatives, 11.6% (SD, 7.2) in controls, and 83.7% (SD, 10.1) in patients with 
acute RF (analysis of variance test between means, P = 0.001). A cut-off of 22.1% of 
D8/17-positive B cells to indicate past RF yielded the highest percentage of correct 
results (95.4%). Delayed staining of whole blood (mean, 0.55 days; SD, 0.2) gave 
equivalent results to immediate staining, but the D8/17 assay on peripheral blood 
mononuclear cells was unreliable.
Conclusions:  The B-cell antigen D8/17 accurately identifies Australians with a past 
history of RF, and the assay is feasible in remote settings with access to facilities capable 
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of performing D8/17 staining within half a day of sample collection.t h
fev
suI as long been observed that rheumaticer (RF) appears to occur only insceptible individuals. This is based on
observations of a familial association,1 con-
trolled studies2,3 and the fact that only a
limited proportion of individuals exposed to
gen known as D8/17 has been investigated
in several population groups. A study of
American and Caribbean people showed
that, in healthy individuals, a mean of
6.12% of B cells were positive for D8/17,
compared with 33.5% in patients with a
past history of RF (P < 0.0001). Intermediate
levels were seen in unaffected first-degree
relatives of index cases, suggesting that
D8/17 might be an inherited factor.9 Subse-
quently, D8/17 was found to be highly
sensitive as a marker for previous RF in the
United States, Mexico, Russia, Chile, and
Israel.10,11 However, in north India it was
less sensitive than other, locally derived B-
cell markers.12-14
The World Health Organization recog-
nises an urgent need to develop new strate-
gies to control RF.15 The ability to identify a
subgroup of individuals at increased risk of
RF could help direct primary prevention
programs.15
The D8/17 non-HLA B-cell antigen has
not been studied in Australia, where Abori-
ginal people have among the world’s high-
est prevalence of rheumatic heart disease
(RHD).16 Populations with the highest rates
of RF and RHD often live far from laborato-
ries with the technology to perform D8/17
assays. Assays for D8/17 expression
described to date usually require testing of
fresh whole blood within 1 or 2 hours of
sample collection, which has made it diffi-
cult to assess D8/17 expression in people
living in remote settings. We aimed to
study the expression of the B-cell marker
D8/17 in Australians with a past history of
RF or RHD, their relatives and healthy
people. We also studied some technical
modifications to the D8/17 assay that
might allow it to be used for people living
in remote settings.
METHODS
Participants were enrolled in three centres:
• a remote Aboriginal community in the
Northern Territory;
• a regional tertiary referral hospital; and
• a tertiary paediatric centre in Melbourne.
Patients with acute RF, past RF (with or
without RHD), healthy relatives of these
patients and healthy volunteers unrelated to
the patients were recruited. The diagnosis of
previous RF was confirmed from medical
notes. In most cases the Jones criteria17 were
supplemented with an echocardiogram
report consistent with RHD. The absence of
a history of RF or RHD in relatives and
controls was documented prospectively by
interview with the individual, review of
medical notes and cardiac auscultation.
Relationship status was determined by a
detailed discussion in the local language.
Ethical approval was obtained from the
Human Research Ethics Committee of Terri-
tory Health Services and Menzies School of
Health Research. Participants were educated
about the study in the local language and
written consent was obtained.
D8/17 staining and flow cytometry
Blood was collected in lithium heparin vacu-
tainers (Becton Dickinson Australia, Sydney,
NSW). Patients’ diagnostic categories were
concealed from laboratory staff. The flow
cytometry assay for D8/17 as described by
Chapman et al was used.18 In brief, either
20 μL of mouse anti-D8/17 monoclonal anti-
body (provided by Professor J Zabriskie,
Rockefeller University, New York, USA) or
5 μL of mouse IgM, lambda (isotype control;
Sigma, Sigma-Aldrich, Sydney, NSW) was
added to 300 μL of whole blood. After 40
minutes’ incubation at 4°C, the samples
were washed with phosphate buffered saline
(PBS). Fluorescein-5-isothiocyanate (FITC)-
labelled goat anti-mouse IgM (μ) antibody
(Caltag, Burlingame, Calif, USA) and phyco-
erythrin-labelled anti-CD19 (Becton Dickin-
son Australia, Sydney, NSW) were added.
After 20 minutes’ incubation at room tem-
perature, red cells were lysed with ammo-
nium chloride lysis solution (150 mM
ammonium chloride, 10 mM potassiumMJA • Volume 184 Number 10 • 15 May 2006 507
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15 minutes. Cells were centrifuged and
washed with PBS before resuspension in PBS
for analysis by flow cytometry.
All analysis was done on a FACS Calibur
flow cytometer (Becton Dickinson Australia,
Sydney, NSW). Lymphocytes were gated
according to their forward and side scatter
profile. To eliminate background fluorescence,
values were set for the quadrants by defining
the isotype control samples (no D8/17 anti-
body) as 99% negative. The fluorescence was
measured and the percentage of D8/17-posi-
tive cells of a set number of CD19-positive
cells was calculated with FlowJo software (Tree
Star, San Carlos, Calif, USA).
Preparation of peripheral blood 
mononuclear cells
For a subset of samples, peripheral blood
mononuclear cells (PBMCs) were isolated
on a Ficoll-Paque PLUS density gradient
(Amersham Pharmacia Biotech, Uppsala,
Sweden), resuspended in RPMI (Roswell
Park Memorial Institute) medium (Gibco,
Invitrogen Australia, Melbourne, VIC), 50%
fetal calf serum, 10% dimethylsulfoxide
(Sigma, Sigma-Aldrich, Sydney, NSW), and
slowly frozen to – 80°C. Frozen PBMCs were
thawed, incubated with antibodies, and
analysed by flow cytometry as described
above. Results obtained using PBMCs were
compared with the results obtained by ana-
lysis of fresh whole blood from the same
patient.
Assessing the effect of delayed 
staining
Transportation of specimens from remote
locations involved delays of up to a day as
well as temperatures in excess of 30°C on
occasion. To assess any effect of time delay
artefact on the accuracy of the D8/17 assay,
38 samples were stained on location in the
community and compared with results
obtained by staining the samples in the
laboratory after a delay of about half a day.
Statistical analysis
Based on published values for D8/17,9 a
sample size of only two patients per group
was needed to differentiate mean B-cell
D8/17 expression between patients with RF
or RHD and control patients, and only four
patients per group were needed to differen-
tiate between patients with RF or RHD and
unaffected family members (power, 90%;
two-sided α, 0.05).
The results were analysed using the Stata
7 statistical package (Stata Corporation,
College Station, Tex, USA). The mean and
standard deviation of the percentage of the B
cells positive for D8/17 were calculated for
the samples from patients in each category.
Analysis of variance (ANOVA) was per-
formed to determine whether a significant
difference existed. The differences between
the means of each of the categories and 95%
confidence intervals were calculated. The
relationship between the results obtained
from first-degree and second-degree rela-
tives were compared by means of Student’s t
test. A receiver operator characteristics
(ROC) curve was constructed from the
results from patients with RF or RHD and
control patients. Results from immediate
and delayed staining were compared graph-
ically, including a Bland–Altman plot.
RESULTS
One hundred and six individuals were
enrolled; all but 19 were Aboriginal (Box 1).
Participants included 42 males and 64
females; the proportions of males and
females did not differ significantly between
the groups.
Box 2 and Box 3 show that D8/17 expres-
sion was different in the four groups
(ANOVA, P < 0.0001) — patients with acute
RF had the highest levels (mean, 83.7%; SD,
10.1), followed in descending order by
patients with RHD or past RF (mean,
39.3%; SD, 11.8), relatives (mean, 22.5%;
SD, 5.2) and controls (mean, 11.6%; SD,
7.3). Aboriginal or non-Aboriginal ethnicity
appeared to have no effect on D8/17 expres-
sion. The difference in mean D8/17 level
between first-degree relatives and second-
degree relatives (22.5% [SD, 5.2] v 16.8%
[SD, 8.7]) approached significance (t test,
P = 0.08), so only first-degree relatives were
included in the analysis. The differences of
the means of all groups were significant and
substantial (greater than 10%).
In the ROC analysis, patients with either
acute RF or a history of past RF or RHD
were defined as positive cases and were
compared with healthy controls. Based on
this analysis, a cut-off of greater than
22.1% of B cells positive for D8/17 yielded
the greatest percentage of accurate results
(95.4%), with a sensitivity of 95.1% and a
2 Percentage of D8/17-positive 
B cells in the four groups of 
participants
RF = rheumatic fever. RHD = rheumatic heart 
disease. P < 0.0001 comparing all four groups by 
analysis of variance. ◆
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1 Demographic features of participants
Demographic 
feature
Category
TotalRF
RHD or 
past RF
First-degree 
relative
Second-degree 
relative Control
Ethnicity
Aboriginal 3 34 7 8 35 87
Non-Aboriginal 0 4 5 0 10 19
Sex
Male 1 16 3 0 22 42
Female 2 22 9 8 23 64
Mean age in 
years (range) 
10 
(8–14)
36 
(19–52)
37 
(11–58)
34 
(19–68)
39 
(4–63)
—
Total 3 38 12 8 45 106
RF = rheumatic fever. RHD = rheumatic heart disease. ◆508 MJA • Volume 184 Number 10 • 15 May 2006
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a positive test at this cut-off was 21.4.
Thus, a patient’s likelihood of having the
disease with a D8/17-positive B-cell level
greater than 22.1% was 21.4 times the
pretest probability. If a negative result
(D8/17-positive B-cell level less than
22.1%) is obtained, the pretest probability
is multiplied by 0.05.
Box 4A shows a good correlation between
the results for the D8/17 analysis of blood
stained immediately and that stained with a
delay of about half a day (mean, 0.55 days;
SD, 0.2) for 38 sample pairs (correlation
coefficient [r] = 0.94). A Bland–Altman plot
(Box 4B) confirmed that differences between
the two methods were not related to the
level of D8/17 positivity. There was poor
correlation between the results of the D8/17
assay obtained from analysis of fresh whole
blood compared with frozen PBMC, in 19
sample pairs (r = 0.32).
DISCUSSION
Our findings indicate that the B-cell antigen
D8/17 is a sensitive and specific marker of
past RF in Australians and are consistent
with those of researchers in the United
States, Mexico, Russia, Chile and Israel.9-
11,19,20 This adds to the growing evidence
that D8/17 may be a universal marker of
past RF in ethnically disparate populations.
Negative findings by some US and north
Indian researchers remain unexplained, but
may reflect ethnic differences in the expres-
sion of B-cell antigens, selection of control
patients, variation in antibody quality, or
technical issues relating to the technique for
selecting B cells.12-14,21
In previous reports, first-degree relatives
have been shown to express D8/17 at inter-
mediate levels, averaging 14.0% of B cells.9
Intermediate expression of D8/17 was also
demonstrated in the relatives of patients
with Sydenham’s chorea.20 These findings
suggest that the B-cell marker is inherited,
possibly along autosomal recessive lines. In
our study, the absolute percentages of B cells
positive for D8/17 in each category (patients
with a past history of RF or RHD, first-
degree relatives and healthy controls) reflect
previous results and increase their reliability
and generalisability.9
It is clear that D8/17 expression is not
merely a marker of streptococcal infection,
as it is not increased in poststreptococcal
glomerulonephritis and uncomplicated
streptococcal tonsillitis.9,22 However, post-
streptococcal reactive arthritis is associated
with elevated levels of D8/17, with D8/17
expression not conclusively differentiating
between RF and poststreptococcal reactive
arthritis in one small series.23
The functional significance of the D8/17
protein remains unknown. It does not
match any known protein or HLA.20,24 The
antibody to D8/17 has been shown to cross-
react with cardiac muscle, skeletal muscle,
smooth muscle cells of blood vessels and
recombinant M6 streptococcal protein.
Adsorption testing showed that B cells from
a patient with RHD inhibited the binding of
the D8/17 antibody to cardiac muscle. It was
thus suggested that the D8/17 antigen may
act as a streptococcal binding site on the B
cells, and consequently become up-regu-
lated after an infection, with B cells acting as
antigen-presenting cells and influencing T-
cell-specific cytotoxicity to heart and brain
cells.22
For the first time, we evaluated D8/17 as a
diagnostic test for RF or RHD by looking at
its receiver operator characteristics, and
found that a cut-off of 22.1% cells positive
for D8/17 was the most accurate break point
to distinguish between affected patients and
healthy controls. Clearly, a positive test
result is not diagnostic of RF or RHD, as
50% of unaffected first-degree relatives and
4% of healthy controls were found to be
positive for D8/17. Rather, D8/17 may be
seen as a marker of susceptibility to RF. The
intermediate level of expression of D8/17 in
unaffected first-degree relatives supports the
conjecture that susceptibility is inherited
rather than acquired. The consistency of the
degree of elevation of D8/17 in first-degree
relatives, but not controls, in a region where
Group A streptococcal (GAS) infection is
endemic suggests that inheritance, rather
than environment or exposure to GAS, is the
cause of the observed difference. Conclusive
proof requires a prospective study of D8/17
expression in a high-risk population.
If D8/17 is an inherited marker of suscep-
tibility to RF, it has a number of potential
useful clinical applications. A cut-off point
could be selected that could “rule out” past
or current RF, which would be particularly
useful in remote-living patients. In popula-
tions with a high incidence of RF, D8/17
3 Comparison of mean D8/17 
expression between categories 
of participants
Categories compared
Difference of the 
mean percentage 
of D8/17-positive 
B cells (95% CI)
Acute RF and controls 72.0 (63.1–81.0)
Acute RF and RHD/
past RF
44.4 (30.2–58.7)
RHD/past RF and 
controls
27.6 (23.4–31.8)
RHD/past RF and 
relatives
16.7 (9.6–23.8)
Relatives and controls 10.9 (6.4–15.4)
RF = rheumatic fever. RHD = rheumatic heart 
disease. ◆
4 Comparison of immediate versus delayed staining
A: Comparison of D8/17 analyses with immediate versus delayed staining.
B: Bland–Altman plot of immediate and delayed staining results. This plot is used to look for 
systematic differences when comparing two measurement techniques and to determine if the 
difference in results between the two techniques may be clinically important. In this case, the results 
with immediate and delayed staining were within 18% of each other on 95% of occasions. ◆
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MEDICINE  AN D THE COMMU NITYcould be used as a screening test to identify
a group at increased risk of developing RF,
who may be suitable for a primary preven-
tion intervention, such as any future GAS
vaccine.
A hypothesis is that D8/17, already
expressed in excess in susceptible patients,
is further augmented by the process that
leads to RF. This suggests that D8/17 might
be incorporated into the Jones criteria for
the diagnosis of acute RF,17 either as an
additional major manifestation, or as an
obligatory feature in all diagnoses of acute
RF. We are presently evaluating this in a
larger, prospective study.
For clinical applicability, a diagnostic test
must be readily available and cost effective.
We looked at one way of reducing the
overheads of this technically sophisticated
test — storing specimens as frozen PBMC so
that they could be tested in batches. We
found that flow cytometry for D8/17 was
not reliable when performed on frozen
PBMC stored at – 80°C. However, we
showed that a delay of up to half a day, such
as that required to transport whole blood
from a remote community to a central labor-
atory, had no significant effect on the accur-
acy of D8/17 analysis. As flow cytometry is
not available in many locations where RF is
common, further studies should investigate
quantitative (rather than simple positive or
negative) D8/17 assays that are cheap and
practical in remote settings.
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